AVITA Medical Inc
NASDAQ:RCEL

Watchlist Manager
AVITA Medical Inc Logo
AVITA Medical Inc
NASDAQ:RCEL
Watchlist
Price: 11.77 USD 2.53% Market Closed
Market Cap: 308.6m USD
Have any thoughts about
AVITA Medical Inc?
Write Note

AVITA Medical Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AVITA Medical Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
AVITA Medical Inc
NASDAQ:RCEL
Total Liabilities
$62.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%
No Stocks Found

AVITA Medical Inc
Glance View

Market Cap
308.6m USD
Industry
Biotechnology

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.

RCEL Intrinsic Value
15.68 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is AVITA Medical Inc's Total Liabilities?
Total Liabilities
62.6m USD

Based on the financial report for Dec 31, 2023, AVITA Medical Inc's Total Liabilities amounts to 62.6m USD.

What is AVITA Medical Inc's Total Liabilities growth rate?
Total Liabilities CAGR 1Y
364%

Over the last year, the Total Liabilities growth was 364%.

Back to Top